CG Oncology, Inc. Common stockCGONNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank25
3Y CAGR-10.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-10.4%/yr
Annual compound
Percentile
P25
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 42.07% |
| 2024 | 79.45% |
| 2023 | 57.61% |
| 2022 | 58.46% |
| 2021 | 0.00% |